Vincze Z, Brugos B
Emergency Department, Division of Clinical Immunology, University of Debrecen, Hungary.
Pharmazie. 2012 May;67(5):419-21.
Dyslipidaemia is a major risk factor of cardiovascular diseases, the role of serum total cholesterol (Chol) especially LDL-Chol is well established in the pathogenesis of atherosclerosis and ischemic heart disease. Use of cholesterol lowering drugs within the first 24 h of hospitalization for acute myocardial infarction (AMI) is associated with a lower rate of cardiogenic shock, arrhythmias, cardiac arrest and recurrent myocardial infarction. We assessed data of 416 patients admitted to hospital with AMI in a 2 year period (2001-2003) focusing on statin therapy. We have not found a correlation between serum lipid parameters and mortality of patients with AMI. Chronic statin treatment used before AMI (in 36 patients) did not influence mortality of patients. Chol level of patients with ST-elevation myocardial infarction (STEMI) was significantly higher (p = 0,043). Mortality of patients who did not receive statin treatment after AMI was significantly higher. These data highlight the importance of early aggressive statin treatment in patients with AMI and necessity of statins in patients with hypercholesterolaemia.
血脂异常是心血管疾病的主要危险因素,血清总胆固醇(Chol)尤其是低密度脂蛋白胆固醇(LDL-Chol)在动脉粥样硬化和缺血性心脏病发病机制中的作用已得到充分证实。急性心肌梗死(AMI)住院后24小时内使用降胆固醇药物与心源性休克、心律失常、心脏骤停及再发心肌梗死的发生率降低相关。我们评估了2001年至2003年这两年期间416例因AMI入院患者的数据,重点关注他汀类药物治疗情况。我们未发现血清脂质参数与AMI患者死亡率之间存在相关性。AMI前使用慢性他汀类药物治疗(36例患者)并未影响患者死亡率。ST段抬高型心肌梗死(STEMI)患者的Chol水平显著更高(p = 0.043)。AMI后未接受他汀类药物治疗的患者死亡率显著更高。这些数据凸显了对AMI患者进行早期积极他汀类药物治疗的重要性以及他汀类药物在高胆固醇血症患者中的必要性。